TAKETake Solutions Limited
Healthcare · Health Information Services · NSE · as of 2026-10-27 (delayed ~30 min in market hours)
TAKE LIMITED, together with its subsidiaries, provides domain-intensive services in life sciences and software and information technology in India. The company offers clinical research, generics development, data sciences, regulatory affairs, and pharmacovigilance and safety services backed by technology expertise. It also provides embed digital and employ mobile solutions for patient centricity insight in life science sector; and payer solutions, including access to billing insight through cloud adoption. In addition, the company offers payer-provider digital solution, which includes personalized medicine, wellness, and patient engagement; and medical device solution, such as technological transformation with chip level programming, DICOM devices, wearables, PROM, nano devices, and miOTs. The company was formerly known as TAKE Solutions Limited and change its name to TAKE LIMITED in June 2026. TAKE LIMITED was incorporated in 2000 and is based in Chennai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on TAKE — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 28/100)
- • Profit growth: -71.0% YoY
- • ROCE: -6.2%
- • RSI: 29
- • MACD: bearish
Bull case
- • ROE: 35.0%
- • Debt/Equity: 0.00
- • Promoter holding: 62.2%
- • Trend strength (ADX): 41
Bear case
- • Profit growth: -71.0% YoY
- • ROCE: -6.2%
- • RSI: 29
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Momentum is fading versus the broader market
- • Profit growth: -71.0% YoY
- • ROCE: -6.2%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹0.86). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.